menu
FOR U.S. HEALTHCARE PROFESSIONALS
Akynzeo

Helsinn Cares AKYNZEO® Patient Access Resources


AKYNZEO® patient affordability and access options

Helsinn Cares offers valuable programs to help support patient affordability of and access to AKYNZEO®. Depending on the patient’s eligibility, resources may be available to reduce patient costs for AKYNZEO®.

AKYNZEO® support programs available for patients are described below. One or more may be right for your patients.


Use the AKYNZEO® co-pay card and pay $0 for AKYNZEO® with the Pay $0 Savings Program*

Co-pay Card

With the AKYNZEO® Pay $0 Savings Program:

*Restrictions apply. Not available to patients enrolled in state or federal healthcare programs, including Medicare, Medicaid, Medigap, VA, DoD, or TRICARE.

Eligibility Criteria: Good toward the purchase of AKYNZEO® prescriptions. No substitutions permitted. Save this card to reuse with each prescription. Not available to patients enrolled in state or federal healthcare programs, including Medicare, Medicaid, Medigap, VA, DoD, or TRICARE. Offer available to MA residents through June 30, 2019. For all other patients, this offer will expire October 3, 2019. May not be combined with any other coupon, discount, prescription savings card, free trial, or other offer. Federal law prohibits the selling, purchasing, trading, or counterfeiting of this card. Such activities may result in imprisonment of 10 years, fines up to $25,000, or both. Void outside the USA and where prohibited by law. Helsinn Therapeutics (U.S.), Inc. reserves the right to rescind, revoke, or amend this offer at any time without notice. Patients and pharmacies are responsible for disclosing to insurance carriers the redemption and value of the card and complying with any other conditions imposed by insurance carriers on third-party payers. The value of this card is not contingent on any prior or future purchases. The card is solely intended to provide savings on any purchase of AKYNZEO® . Use of the card for any one purchase does not obligate the patient to make future purchases of AKYNZEO® or any other product.


Helsinn Cares Patient Assistance Program

Enrollment in Helsinn Cares is required to assess the eligibility for the Patient Assistance Program.

Helsinn Cares Patient Assistance Program has been specifically designed to assist patients on AKYNZEO® pay for their medication.

Enrollment Form
<-

Get the
Patient
Assistance
Enrollment
Form here.

Download Form

Remember: Helsinn Cares resources help ensure access to Helsinn medications.

Helsinn is committed to helping every patient obtain the Helsinn medication he or she needs. For answers to specific questions, please call 1‑84HELSINN‑U (1‑844‑357‑4668), select prompt 1 for medical information; select prompt 2 for Helsinn Cares.

 

Indication and Important Safety Information

AKYNZEO (netupitant/palonosetron) capsules is indicated in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy.

AKYNZEO (fosnetupitant/palonosetron) for injection is indicated in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy.

Limitations of Use

AKYNZEO for injection has not been studied for the prevention of nausea and vomiting associated with anthracycline plus cyclophosphamide chemotherapy.

AKYNZEO is a combination of palonosetron, a serotonin-3 (5-HT3) receptor antagonist, and netupitant or fosnetupitant, substance P/neurokinin-1 (NK-1) receptor antagonists: palonosetron prevents nausea and vomiting during the acute phase and netupitant/fosnetupitant prevents nausea and vomiting during both the acute and delayed phase after cancer chemotherapy.

Important Safety Information

Warnings and Precautions

 

Adverse Reactions

Drug Interactions

Use in Specific Populations

For more information about AKYNZEO please see the full Prescribing Information

To report SUSPECTED ADVERSE REACTIONS, contact Helsinn at 1‑84HELSINN‑U (1‑844‑357‑4668), select prompt 1, or FDA at 1‑800‑FDA‑1088 or www.fda.gov/medwatch.

Reference:

1. AKYNZEO® Full Prescribing Information.

Expand

Indication and Important Safety Information

AKYNZEO (netupitant/palonosetron) capsules is indicated in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy.

AKYNZEO (fosnetupitant/palonosetron) for injection is indicated in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy.

Limitations of Use

AKYNZEO for injection has not been studied for the prevention of nausea and vomiting associated with anthracycline plus cyclophosphamide chemotherapy.

AKYNZEO is a combination of palonosetron, a serotonin-3 (5-HT3) receptor antagonist, and netupitant or fosnetupitant, substance P/neurokinin-1 (NK-1) receptor antagonists: palonosetron prevents nausea and vomiting during the acute phase and netupitant/fosnetupitant prevents nausea and vomiting during both the acute and delayed phase after cancer chemotherapy.

Important Safety Information

Warnings and Precautions

 

Adverse Reactions

Drug Interactions

Use in Specific Populations

For more information about AKYNZEO please see the full Prescribing Information

To report SUSPECTED ADVERSE REACTIONS, contact Helsinn at 1‑84HELSINN‑U (1‑844‑357‑4668), select prompt 1, or FDA at 1‑800‑FDA‑1088 or www.fda.gov/medwatch.

Reference:

1. AKYNZEO® Full Prescribing Information.

Indication

AKYNZEO is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy. AKYNZEO is an oral fixed combination of palonosetron and netupitant: palonosetron prevents nausea and vomiting during the acute phase and netupitant prevents nausea and vomiting during both the acute and delayed phase after cancer chemotherapy.1